SEHK:1672Biotechs
Is Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?
Ascletis Pharma recently reported that its next-generation triple peptide agonist ASC37 achieved greater weight loss than tirzepatide in diet‑induced obese mice, and outlined plans to file investigational new drug applications for both once‑monthly subcutaneous and oral formulations in the third quarter of 2026.
The company also highlighted that ASC37 and its dual agonist ASC35 qualify as biologics, potentially benefiting from longer U.S. exclusivity and reduced exposure to government price...